Department of Life Science Informatics, B-IT, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität , Dahlmannstrasse 2, D-53113 Bonn, Germany.
J Med Chem. 2015 Jan 8;58(1):30-40. doi: 10.1021/jm5008159. Epub 2014 Jul 30.
Publicly available kinase inhibitors have been analyzed in detail. Nearly 19000 inhibitors have been identified with activity against 266 different kinases. Thus, about half of the human kinome is currently covered with active small molecules. The distribution of inhibitors across the kinome is uneven. Most available kinase inhibitors are likely to be type I inhibitors. By contrast, type II inhibitors are rare but usually have high potency. Kinase inhibitors generally display high scaffold diversity. Activity cliffs with an at least 100-fold difference in potency are only found for inhibitors of 106 kinases, which is partly due to only small numbers of compounds available for many kinases, in addition to scaffold diversity. Moreover, kinase inhibitors are less promiscuous than often thought. More than 70% of available inhibitors are only annotated with a single kinase activity, and only ∼1% of the inhibitors are active against five or more kinases.
已对公开可用的激酶抑制剂进行了详细分析。已经鉴定出近 19000 种对 266 种不同激酶具有活性的抑制剂。因此,目前约有一半的人类激酶组被具有活性的小分子覆盖。抑制剂在激酶组中的分布不均匀。大多数可用的激酶抑制剂可能是 I 型抑制剂。相比之下,II 型抑制剂很少见,但通常具有高活性。激酶抑制剂通常具有很高的支架多样性。只有 106 种激酶的抑制剂才会出现活性悬崖,其活性差异至少为 100 倍,这部分是由于许多激酶的化合物数量较少,此外还有支架多样性。此外,激酶抑制剂的不专一性并不像人们想象的那么高。超过 70%的可用抑制剂仅被注释为一种激酶活性,只有约 1%的抑制剂对五种或更多激酶具有活性。